Results 51 to 60 of about 1,793 (169)
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi +13 more
wiley +1 more source
Dupilumab's bidirectional effects on alopecia areata: A systematic review
Background: Dupilumab inhibits interleukin-4 and interleukin-13 signaling and is used for atopic dermatitis and other type 2 inflammatory diseases, but its relationship with alopecia areata (AA) remains paradoxical. Objective: To characterize AA outcomes
Gerardo Guilarte, BS +5 more
doaj +1 more source
Molecular signatures define alopecia areata subtypes and transcriptional biomarkers
Alopecia areata (AA) is an autoimmune disease typified by nonscarring hair loss with a variable clinical course. In this study, we conducted whole genome gene expression analysis of 96 human scalp skin biopsy specimens from AA or normal control subjects.
Ali Jabbari +9 more
doaj +1 more source
Family quality‐of‐life burden in chronic spontaneous urticaria: A multicentre study
Poor control of chronic spontaneous urticaria (CSU) significantly worsens family members' quality of life, especially in emotional, physical, and social domains. Higher disease severity was linked to increased caregiving burden and household expenditures, highlighting the need for family‐centred CSU care and support across diverse global populations ...
Beatrice Martinez Zugaib Abdalla +33 more
wiley +1 more source
Turban PUVASOL: An effective treatment in alopecia totalis
Alopecia areata is characterized by patchy hair loss involving the scalp, eyelashes, and beard. The disease may at times lead to complete baldness of the scalp (alopecia totalis) or of the entire body (alopecia universalis). Alopecia totalis is usually resistant to therapy.
Sornakumar, L +2 more
openaire +3 more sources
ABSTRACT A 31‐year‐old man with severe, corticosteroid‐resistant alopecia areata presented with substantial scalp hair loss (Severity of Alopecia Tool [SALT] score: 60%) despite a 1‐year regimen of topical corticosteroids, 5% minoxidil, and oral prednisolone. He was treated with allogeneic exosomes derived from adipose tissue mesenchymal stromal cells (
Masoumeh Kianpisheh +4 more
wiley +1 more source
S3‐Leitlinie Diagnostik und Therapie der Alopecia areata – Teil 1: Diagnostik und Epidemiologie
Zusammenfassung In dem vom Innovationsausschuss beim gemeinsamen Bundesausschuss (G‐BA) geförderten Projekt wurde von 2023 bis 2025 die S3‐Leitlinie zur Diagnostik und Therapie der Alopecia areata (AA) entwickelt. Die interdisziplinäre Expertengruppe bestand aus Vertretern der Deutschen Dermatologischen Gesellschaft, insbesondere aus der AG ...
Ulrike Blume‐Peytavi +13 more
wiley +1 more source
S3 guideline diagnostics and therapy of alopecia areata – Part 1: Diagnostics and epidemiology
Summary In the project funded by the Innovation Committee at the G‐BA, the S3 guideline for the diagnosis and treatment of AA was developed between 2023 and 2025. The interdisciplinary expert panel consisted of representatives from the German Dermatological Society, in particular from the Pediatric Dermatology Working Group, the Professional ...
Ulrike Blume‐Peytavi +13 more
wiley +1 more source
Azathioprine, an analog of mercaptopurine, is used for various inflammatory/autoimmune diseases in diverse fields such as rheumatology, ophthalmology, gastroenterology, and neurology.
Debashish Mishra +4 more
doaj +1 more source
ABSTRACT Background and Aims Stevens‐Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme major (EM major) are severe dermatologic conditions characterized by varying degrees of skin detachment and involvement of mucosal membranes, often triggered by drug reactions or infections.
Sadaf Salehi +6 more
wiley +1 more source

